CPT code 87799 – Infectious agent detection, nucleic acid, quantitative NOS

Key takeaways

CPT code 87799 covers quantification of an infectious agent by nucleic acid when the organism has no specific CPT code of its own.

87798 is the amplified probe NOS code, while 87799 is the quantification NOS code.

87799 is a Category I not otherwise specified code with a published Medicare CLFS rate, not an unlisted code.

Payers still review 87799 claims closely, so the note should name the organism, the method and the medical necessity.

Pabau’s practice management software validates each claim before submission and carries prior authorization codes from the appointment through to the claim.

CPT code 87799: Official descriptor and code definition

CPT code 87799 is defined by the AMA as: “Infectious agent detection by nucleic acid (DNA or RNA); not otherwise specified, quantification, each organism.” In practice, it is the code for a lab test that measures how much of an organism is present. It applies only when that organism has no quantification code of its own. Four elements of the descriptor decide when it applies.

When to use 87799: Confirm that the organism has no specific CPT code before billing 87799. The code set includes quantification codes for Chlamydia trachomatis (87492), gonorrhea (87592), HIV-1 (87536), hepatitis C (87522), CMV (87497) and many more. If the organism has its own quantification code, bill that code instead. The chart below maps that first check and the four sibling codes in the family.

Clinical applications and use cases for CPT 87799

Several clinical scenarios land on CPT code 87799 rather than a specific code. Most involve measuring the load of an organism that the CPT code set has not given a dedicated code.

• Antibiotic treatment monitoring: Quantifying bacterial load before and after treatment shows whether therapy is working. Serial quantitative assays for a less common organism, such as Mycoplasma genitalium, can bill under 87799 because it has no quantification code.
• Genitourinary pathogens without dedicated codes: Some GU organisms detected by NAAT have no named code. A quantitative assay for one of these organisms bills under 87799.
• Emerging and novel molecular assays: New diagnostic tests often reach clinical use before the AMA assigns a specific CPT code. Until that code is published, a quantitative nucleic acid test for the organism is reported with 87799.
• Viral load monitoring for less common viruses: Parvovirus B19 has no dedicated quantification code, so reference labs list quantitative parvovirus B19 PCR under 87799. Load monitoring in immunocompromised patients often follows the same route.
• Post-transplant surveillance: Quantitative monitoring for an opportunistic infection in a transplant recipient bills under 87799 when the organism has no named quantification code.

CPT 87799 vs. 87798: How to choose the right code

CPT 87798 is the amplified probe technique code, and CPT 87799 is the quantification code. Both are not otherwise specified codes for a single organism, reported per organism. Mixing the two up is a frequent source of miscoding in this range.

A practical billing check: Look at the laboratory report. A “detected” or “not detected” result from an amplified assay points to 87798. A copy number, IU/mL or log value points to CPT code 87799. This is a working rule rather than descriptor text, since the descriptors split on technique and quantification. Billing 87799 for a qualitative result overstates the service and carries compliance risk.

Medicare and payer reimbursement for CPT code 87799

Medicare reimburses CPT code 87799 under the Clinical Laboratory Fee Schedule (CLFS), which CMS publishes annually. The code is a Category I not otherwise specified code rather than an unlisted code, so it carries its own published CLFS rate. Commercial payers set their own rates, often with the CLFS figure as a reference point.

Several practical reimbursement considerations apply specifically to this code:

• Rate subject to annual update: The CLFS rate for 87799 can change each calendar year. Check the current CMS file before quoting expected reimbursement to a patient or setting fee schedules.
• Commercial payer variability: Commercial payers may pay a percentage of their own fee schedule or of the Medicare CLFS rate. Some payer policies exclude 87799 for certain indications, so verify coverage before ordering.
• Medicaid rate differences: State Medicaid programs set their own lab fee schedules and may not cover 87799 for every clinical indication. Check the applicable state’s fee schedule.
• CLIA certification required: The performing laboratory must hold CLIA certification at the complexity level appropriate for molecular amplification assays. Claims submitted by uncertified labs are rejected regardless of coding accuracy.

Documentation requirements for CPT 87799 medical necessity

A not otherwise specified code can draw closer payer review than an organism-specific one, because the code itself does not name the organism. For medical billing compliance, every 87799 claim needs the following elements in the medical record.

• Clinical indication: The ordering provider’s note must state why a quantified result was medically necessary at this encounter, tied to a specific diagnosis.
• Organism name: Documentation must name the specific organism targeted by the assay. “Infectious agent” is insufficient. “Quantitative Parvovirus B19 PCR” is acceptable.
• Methodology: Record the method used, such as PCR, RT-PCR or another nucleic acid technique. This shows the test meets the code’s nucleic acid requirement.
• Result format: The lab report showing a quantitative result must be available for payer review. Qualitative reports do not support 87799.
• Explanation of why no specific code exists: The note or letter of medical necessity should name the specific CPT codes considered and why none applied. This protects against a denial on the grounds that a more specific code exists.
• ICD-10 diagnosis code alignment: The diagnosis code on the claim must logically support the need for quantitative pathogen detection. Document the clinical rationale linking the diagnosis to the test ordered.

Complete this checklist before the claim goes out. Payers reviewing 87799 claims often request the ordering note and the laboratory report together, so having both ready speeds up any records request. The guide to submitting a clean claim covers the broader claim preparation process.

ICD-10 codes to pair with CPT 87799

The CDC ICD-10-CM tool is the authoritative source for selecting supporting diagnosis codes. Common ICD-10 pairings by clinical scenario are shown below.

The ICD-10 code has to show why quantitative testing was medically necessary for this patient. “Viral infection, unspecified” alone is weaker support than a specific organism code with a note on how the load result changes management. Payer reviewers look for that clinical logic.

Prior authorization requirements for CPT 87799 molecular testing

Prior authorization rules for molecular tests billed under 87799 differ by payer type. Completing insurance eligibility verification before ordering the test is the surest way to catch a prior auth requirement before the service is performed.

• Medicare: Traditional Medicare does not routinely require prior authorization for laboratory tests paid under the CLFS, including 87799. Medicare Administrative Contractors (MACs) may still apply Local Coverage Determinations (LCDs) that restrict payment to specific indications.
• Medicare Advantage plans: These are managed by private insurers and frequently require prior authorization for molecular diagnostics. Treat Medicare Advantage as commercial insurance for prior auth purposes.
• Commercial insurers: Prior auth requirements vary by plan and change annually. Many commercial plans require prior auth for molecular assays above a cost threshold, which can capture 87799.
• Medicaid managed care: State Medicaid managed care organizations often require prior auth for not otherwise specified molecular codes. Policies differ by state and by managed care organization within the same state.

When prior auth is required, payers typically ask for the organism, the assay method and the clinical indication tied to a diagnosis code. Most also want a note explaining why no specific CPT code applies. Build a standard prior auth request template for 87799 submissions to streamline the process.

Common denial reasons for CPT code 87799 and how to resolve them

Claims for CPT code 87799 can draw closer payer review than organism-specific codes, because the code does not name the organism. Effective denial management workflows for this code start with the most frequent denial reasons and their fixes.

How to appeal a denied CPT 87799 claim

A structured appeal works better than a generic reconsideration request. For a denied 87799 claim, follow these steps.

1. Identify the denial reason code on the Explanation of Benefits (EOB) or Electronic Remittance Advice (ERA). The CARC code identifies the specific denial category, which determines what documentation to gather. The list of common denial codes explains what each CARC means.
2. Write a targeted letter of medical necessity. State the patient’s clinical situation, the organism targeted, and why a quantified result was necessary for clinical management. Then confirm that no specific CPT code covers this organism and method.
3. Attach supporting documentation. Include the ordering provider’s clinical note and the lab report showing the quantitative result. If the payer is unfamiliar with the assay, add peer-reviewed literature on load quantification for this organism.
4. Submit within the payer’s appeal window. Most commercial payers allow 60-180 days from the denial date. Medicare Part B appeals at the redetermination level must be filed within 120 days of the initial determination.
5. Escalate to medical director review if the first-level appeal is denied. Many payers will grant a peer-to-peer call between the reviewing medical director and the ordering provider, which often resolves medically complex denials.

How practice management software helps with CPT 87799 billing

An 87799 claim needs the organism, the method and the medical necessity rationale to travel together. In many practices those details sit in the order, the lab report and a billing note. Each missing piece gives a payer a reason to deny or request records.

Pabau’s claims management software scrubs each claim for missing or invalid details before it is submitted. Prior authorizations are stored as cases, so the authorization code follows the appointment through to the claim. A claim still missing its code is flagged so your team can assign one.

In the US, Pabau submits CMS-1500 claims through Claim.MD to thousands of payers. You can run a real-time eligibility check before the test is ordered, and remittance advice flows back into the same claims dashboard. A coverage exclusion found at that point costs a phone call rather than an appeal.

Catch 87799 claim errors before submission

Pabau’s claims management software validates each claim before it goes out and keeps prior authorization codes attached from booking to claim. Your billing team spends less time on resubmissions and appeals.

Book a demo

Conclusion

CPT code 87799 is the right choice for a quantified nucleic acid result when the organism has no code of its own. It has a published CLFS rate, so the payment risk sits in the record rather than the rate.

Before each 87799 claim, make two checks. Confirm that no organism-specific quantification code exists, and confirm that the lab report shows a numeric result. A claim that passes both, with the indication written into the note, gives a payer little reason to ask for more.

Pabau’s Claim.MD clearinghouse integration runs real-time eligibility checks before the visit and returns remittance advice to your claims dashboard. Book a demo to see how Pabau carries a lab claim from order to payment.

Continue your research

Need to understand how clearinghouse submission works? Medical claims clearinghouse guide explains how clearinghouses validate, route, and report on claims before they reach payers.

Building a denial prevention workflow? Electronic remittance advice explained covers how to read ERA files, interpret CARC codes, and feed denial data back into your billing process.

Looking for a complete billing compliance framework? What is medical billing walks through the full claim lifecycle from patient registration to payment posting.

Frequently asked questions